In the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome (HLHS), Mayo Clinic physicians, scientists and many other experts are working collaboratively to find and apply innovative solutions for HLHS.
In HLHS, a rare and complex congenital heart defect, the left side of the heart is severely underdeveloped. Treatment for HLHS today is palliative — there is no cure — and typically involves a series of three surgical procedures.
To better understand and treat HLHS, the program is taking a multifaceted approach that includes research into imaging and outcomes, human genetics, and regenerative strategies, as well as the creation of an annotated biorepository.
The program's goal is to launch clinical trials that offer the latest advances in cell therapy to people with HLHS. Ultimately, program leaders hope their research will result in the ability to delay, or even prevent, the need for heart transplants in people with the disease.
Learn more about the program's team approach and how you can participate in HLHS research.
Read about current news and events on the HLHS Cause to Cure Blog.